Adjuvo is delighted to announce that it has led a £5.2 million investment round for Eco-inject, the medical device company reinventing the autoinjector.

Autoinjectors are becoming central to modern healthcare, driven by the expanding class of patient-administered injectable therapies. Yet today’s devices remain complex, costly, and carbon-intensive, with the market expected to reach 2 billion units by 2030.

Eco-Inject has redesigned the autoinjector from first principles, creating a patented, bio-based platform that reduces component complexity and carbon emissions without increasing cost. Its scalable, GMP-ready design enables integration into pharmaceutical manufacturing and supports commercial deployment at global scale.

“Eco-Inject is redefining what autoinjectors can be – sustainable, scalable, and ready to meet the demands of today’s healthcare market. Adjuvo is hugely excited to support the team as they commercialise this platform and deliver more cost-effective autoinjectors to healthcare providers and users in everyday care.”

Adjuvo’s investment recognises that Eco-Inject is working to deliver a product that the industry demands. The platform offers a seamless transition for pharmaceutical customers for whom cost and carbon reductions are important.

 
You can read more about this investment in the full article published by Business Weekly here.